Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 9, 2015, 40 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,745.00 to $198,813,900.00.

Highlighted Stocks Traded by Insiders:

KMG Chemicals (KMG) - FREE Research Report

Hatcher David L, who is 10% Owner at KMG Chemicals, sold 1,500 shares at $29.82 on April 9, 2015. Following this transaction, the 10% Owner owned 2.0 million shares meaning that the stake was reduced by 0.07% with the 1,500-share transaction.

The shares most recently traded at $30.00, up $0.18, or 0.6% since the insider transaction. Historical insider transactions for KMG Chemicals go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 6,500
  • 24-Week # shares bought: 7,000
  • 24-Week # shares sold: 6,500

The average volume for KMG Chemicals has been 39,200 shares per day over the past 30 days. KMG Chemicals has a market cap of $349.1 million and is part of the basic materials sector and chemicals industry. Shares are up 49.5% year-to-date as of the close of trading on Thursday.

KMG Chemicals, Inc., through its subsidiaries, engages in the manufacture, formulation, and distribution of specialty chemicals in the United States, Mexico, Canada, Europe, Israel, and Singapore. It operates in two segments, Electronic Chemicals and Wood Treating Chemicals. The stock currently has a dividend yield of 0.4%. The company has a P/E ratio of 49.8. Currently, there is 1 analyst who rates KMG Chemicals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMG - FREE

TheStreet Quant Ratings rates KMG Chemicals as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full KMG Chemicals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NxStage Medical (NXTM) - FREE Research Report

Turk Joseph E Jr, who is President at NxStage Medical, sold 1,500 shares at $18.34 on April 9, 2015. Following this transaction, the President owned 124,163 shares meaning that the stake was reduced by 1.19% with the 1,500-share transaction.

The shares most recently traded at $18.29, down $0.05, or 0.27% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 7,000
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 31,232

The average volume for NxStage Medical has been 418,200 shares per day over the past 30 days. NxStage Medical has a market cap of $1.2 billion and is part of the health care sector and health services industry. Shares are up 1.67% year-to-date as of the close of trading on Thursday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings rates NxStage Medical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full NxStage Medical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Darden Restaurants (DRI) - FREE Research Report

Lee Eugene I Jr, who is Chief Executive Officer at Darden Restaurants, bought 7,600 shares at $66.29 on April 9, 2015. Following this transaction, the Chief Executive Officer owned 66,793 shares meaning that the stake was boosted by 12.84% with the 7,600-share transaction.

The shares most recently traded at $67.84, up $1.55, or 2.28% since the insider transaction. Historical insider transactions for Darden Restaurants go as follows:

  • 4-Week # shares sold: 1,808
  • 12-Week # shares sold: 1,808
  • 24-Week # shares sold: 15,505

The average volume for Darden Restaurants has been 1.5 million shares per day over the past 30 days. Darden Restaurants has a market cap of $8.5 billion and is part of the services sector and leisure industry. Shares are up 14.58% year-to-date as of the close of trading on Thursday.

Darden Restaurants, Inc. owns and operates full service restaurants in the United States and Canada. It operates restaurants under the Olive Garden, LongHorn Steakhouse, Bahama Breeze, Seasons 52, The Capital Grille, Eddie V's, and Yard House brand names. The stock currently has a dividend yield of 3.26%. The company has a P/E ratio of 70.3. Currently, there are 10 analysts who rate Darden Restaurants a buy, 1 analyst rates it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DRI - FREE

TheStreet Quant Ratings rates Darden Restaurants as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Darden Restaurants Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null